

- in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. *Stroke* **34**: 2323-2330, 2003
- 35) Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, et al: Donepezil in vascular dementia: a randomized, placebo-controlled study. *Neurology* **61**: 479-486, 2003
- 36) Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, et al: Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. *Dement Geriatr Cogn Disord* **20**: 338-344, 2005
- 37) Wilkinson D, Roman G, Salloway S, Hecker J, Boundy K, et al: The long-term efficacy and tolerability of donepezil in patients with vascular dementia. *Int J Geriatr Psychiatry* **25**: 305-313, 2010
- 38) Erkinjuntti TJ, Kurz A, Gauthier S, Bullock R, Lilienfeld S, et al: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. *Lancet* **359**: 1283-1290, 2002
- 39) Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, et al: Galantamine treatment of vascular dementia: a randomized trial. *Neurology* **69**: 448-458, 2007
- 40) Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, et al: Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. *Curr Med Res Opin* **24**: 2561-2574, 2008
- 41) Coppus AMW, Schuur M, Vergeer J, Janssens ACJW, Oostra BA, et al: Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome. *Neurobiol Aging* **33**: 1988-1994, 2012
- 42) Kondoh T, Kanno A, Itoh H, Nakashima M, Honda R, et al: Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial. *Int J Psychiatry Med* **41**: 71-89, 2011

BRAIN and NERVE 66(5): 507-516, 2014 *Topics*

Title **Acetylcholinesterase Inhibitors for Treatment of Alzheimer's Disease**

Authors Shunichiro Shinagawa^{1)*}, Masahiro Shigeta²⁾

¹⁾Department of Psychiatry, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo 105-8461, Japan; ²⁾Faculty of Health and Sciences, Tokyo Metropolitan University

*E-mail: shinagawa@jikei.ac.jp

Abstract Alzheimer's disease (AD) is a neurodegenerative disorder, and is the commonest cause of dementia. Acetylcholinesterase inhibitors (AChEIs) were developed under the cholinergic hypothesis of AD. Therapeutic strategies with these drugs aimed to enhance cholinergic neurotransmission in specific parts of the brain, and to improve the clinical symptoms of AD. Donepezil, galantamine and rivastigmine are commonly used AChEIs in pharmacotherapy for AD, slowing the progression and controlling the symptoms of AD. Although these drugs have different pharmacological properties, there is no clear evidence of differences between them with respect to efficacy. It is possible to adapt AChEIs for the pharmacotherapy of other conditions, such as vascular dementia, dementia with Lewy bodies, and Down syndrome.

Key words **Alzheimer's disease, acetylcholinesterase inhibitor, donepezil, galantamine, rivastigmine**

MEDICAL BOOK INFORMATION

医学書院

外来で目をまわさない

めまい診療シンプルアプローチ

城倉 健

●B5 頁152 2013年
定価: 本体4,500円+税
[ISBN978-4-260-01833-3]

ありふれた症候でありながら、苦手意識を持つ医師が多い「めまい」。本書は、脳卒中の専門家である著者が、危ないめまいを見逃さないためのフローチャートを用いた簡単・便利なアプローチ法を伝授。めまいの鑑別診断からその対応まで、やさしい語り口でコンサイズに解説。さらにQRコードによる動画配信で眼振や治療法の理解がもっと深まること間違いなし。研修医から内科医、開業医まで、これ1冊でもう対応に迷わない!

